ALTRUBIO

altrubio-logo

AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discover... y and development of novel therapeutics for unmet medical needs. Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics. Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages.

#SimilarOrganizations #People #Financial #Event #Website #More

ALTRUBIO

Social Links:

Industry:
Biotechnology Health Care Medical

Founded:
2000-06-01

Address:
Los Altos, California, United States

Country:
United States

Website Url:
http://www.altrubio.com

Total Employee:
11+

Status:
Active

Contact:
(650) 988-9912

Email Addresses:
[email protected]

Total Funding:
327.61 M USD

Technology used in webpage:
Mobile Non Scaleable Content U.S. Server Location CrUX Dataset CrUX Top 10m Amazon Frankfurt Region Laravel


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

cel-sci-logo

CEL-SCI

CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.

edison-pharmaceuticals-logo

Edison Pharmaceuticals

Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.

synta-pharmaceuticals-logo

Synta Pharmaceuticals

Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.

vital-therapies-logo

Vital Therapies

Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.


Current Advisors List

judy-chou_image

Judy Chou President & CEO @ AltruBio
Board_member
2020-01-01

Current Employees Featured

jeroen-grasman_image

Jeroen Grasman
Jeroen Grasman CFO @ AltruBio
CFO
2021-08-01

not_available_image

Shih-Yao Lin
Shih-Yao Lin Chief Medical Officer @ AltruBio
Chief Medical Officer

Founder


rong-hwa-lin_image

Rong-Hwa Lin

Investors List

soleus-capital_image

Soleus Capital

Soleus Capital investment in Series B - AltruBio

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - AltruBio

blackstone_image

Blackstone Group

Blackstone Group investment in Series B - AltruBio

amoon_image

aMoon Fund

aMoon Fund investment in Series B - AltruBio

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series B - AltruBio

delos-capital_image

Delos Capital

Delos Capital investment in Series B - AltruBio

biotechnology-value-fund_image

Biotechnology Value Fund

Biotechnology Value Fund investment in Series B - AltruBio

camcapital_image

CAM Capital

CAM Capital investment in Series A - AltruBio

amoon_image

aMoon Fund

aMoon Fund investment in Series A - AltruBio

biotechnology-value-fund_image

Biotechnology Value Fund

Biotechnology Value Fund investment in Series A - AltruBio

Official Site Inspections

http://www.altrubio.com Semrush global rank: 5.08 M Semrush visits lastest month: 1.58 K

Unable to get host informations!!!

Loading ...

More informations about "AltruBio"

AltruBio

Before taking on her current roles, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayerโ€™s โ€ฆSee details»

AltruBio Inc. - LinkedIn

Dr. Judy Chou, PhD, is the President, CEO, and member of the Board of Directors of AltruBio Inc., Inc., a clinical-stage biotech company focused on developing novel therapeutics for the โ€ฆSee details»

Org Chart AltruBio - The Official Board

The organizational chart of AltruBio displays its 14 main executives including Judy Chou, Jeroen Grasman and Gene LeeSee details»

AltruBio Company Profile | Management and Employees List

AltruBio is a global biopharmaceutical organization that focuses on the development of targeted antibody therapeutics for the treatment of cancer and immune related inflammatory disease. โ€ฆSee details»

AltruBio - Directors Team - The Org

The Directors Team at AltruBio is responsible for guiding the strategic direction of the company, overseeing major business initiatives, and ensuring the successful development and โ€ฆSee details»

AltruBio Company Profile 2024: Valuation, Funding & Investors

Information on valuation, funding, cap tables, investors, and executives for AltruBio. Use the PitchBook Platform to explore the full profile.See details»

AltruBio

More. 2024 . 01 . 12 . Investor's Business Dailyโ”€Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space. 2023 .See details»

Altrubio Inc. Company Profile | San Francisco, CA | Competitors ...

Find company research, competitor information, contact details & financial data for Altrubio Inc. of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»

AltruBio - Products, Competitors, Financials, Employees, โ€ฆ

AltruBio Announces Formation of Scientific Advisory Board. Dec 3, 2024. World-renowned researchers with extensive experience in immunology and autoimmune diseases join AltruBio โ€ฆSee details»

AltruBio President and CEO Judy Chou Appointed to the โ€ฆ

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (โ€œAltruBioโ€ or โ€œthe Companyโ€), a clinical stage biotech company dedicated to the development of novel โ€ฆSee details»

AltruBio Inc. - BioCentury Company Profiles - BCIQ

May 23, 2024 AltruBio Inc. - BioCentury Company Profiles for the biopharma industrySee details»

AltruBio, Inc. - VentureRadar

"AltruBio is developing first-in-class immune-modulators to target diseases of the immune system. Its world-class global team brings a breadth of expertise in immunology and drug development โ€ฆSee details»

New name, new board, new focus: AltruBio relaunches with $63M โ€ฆ

Apr 15, 2021 AltruBio CEO Judy Chou, Ph.D. (AltruBio) AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name โ€ฆSee details»

AltruBio President and CEO Judy Chou Appointed to the

Nov 1, 2022 CIRM is a State-funded organization that provides grant awards for research with a goal of accelerating world class science to deliver transformative regenerative medicine โ€ฆSee details»

AltruBio - Company Profile - Tracxn

Dec 6, 2024 AltruBio - Developer of drugs for immune-mediated inflammation and cancer therapies. Raised a total funding of $288M over 2 rounds from 8 investors. Founded by Ron โ€ฆSee details»

AltruBio lands up to $225M after shift to immune drug research

May 21, 2024 Dive Brief: Biotechnology startup AltruBio on Tuesday raised a Series B round that could hand it up to $225 million, cashing in again on a decision four years ago to change its โ€ฆSee details»

AltruBio snags a CMO after pivot from oncology to immunology

Sep 13, 2021 Previously known as AbGenomics Holding, AltruBio changed its focus from oncology to immunology in April this year. The company is developing antibody treatments for โ€ฆSee details»

Immune checkpoint enhancer biotech AltruBio raises $225m

May 22, 2024 A healthy run of nine-figure private rounds for biotechs in the US has continued with an impressive $225 million Series B for immunotherapy specialist AltruBio.See details»

AltruBio raises $225M for midphase ulcerative colitis program

May 21, 2024 AltruBio put ALTB-268 through a phase 1 study in healthy volunteers in 2023, leading to the initiation of a midphase study in patients with ulcerative colitis who are refractory โ€ฆSee details»

Ale Rubio - FIT by You

Únete a una comunidad que integra entrenamiento, nutrición y wellness. Con un enfoque preciso y confiable que se ajusta a tus necesidades, horarios y siempre impulsándote hacia adelante โ€ฆSee details»

linkstock.net © 2022. All rights reserved